| 摘要 |
A pharmaceutical composition containing an agent (A) that: (a) inhibits expression or activity of a tumor-associated antigen (TAg); (b) has selective tumor-inhibiting activity against cells with (abnormal) expression of TAg; or (c) increases the amount of complex formed between an HLA (human leukocyte antigen) molecule and TAg, or its fragment, is new. A pharmaceutical composition containing an agent (A) that: (a) inhibits expression or activity of a tumor-associated antigen (TAg); (b) has selective tumor-inhibiting activity against cells with (abnormal) expression of TAg; or (c) increases the amount of complex formed between an HLA (human leukocyte antigen) molecule and TAg, or its fragment. TAg is encoded by nucleic acid (NA) that: (a) comprises any of 28 defined sequences given in the specification, or their fragments; (b) can hybridize to (a) under stringent conditions; (c) is a degenerate version of (a) or (b); or (d) is complementary to (a)-(c). Independent claims are also included for: (1) a pharmaceutical composition containing one or more of TAg, NA encoding TAg, antibody that binds to TAg, antisense sequences specific for NA, host cells that express TAg, or isolated complex of TAg with an HLA molecule (TAg may always by a fragment); (2) diagnosing diseases associated with (abnormal) expression of TAg (M1); (3) determining regression, progression or outbreak of diseases associated with (abnormal) expression of TAg (M2); (4) treating diseases associated with (abnormal) expression of TAg (M3); (5) NA as new compounds; (6) a nucleic acid (NA1) that encodes any of 35 specified peptide sequences or their fragments; (7) a recombinant DNA or RNA (NA2) that includes NA or NA1; (8) a host cell containing NA, NA1 or NA2; (9) proteins encoded by NA1 and their fragments that are immunogenic or can bind to HLA receptors or human antibodies; (10) agents (B) that bind specifically to a protein encoded by NA; (11) antibodies (Ab) that bind specifically to a complex of: (a) protein or its fragments encoded by NA; and (b) Major Histocompatibility (MHC) molecules to which (a) bind, but does not bind to (i) or (ii) singly; (12) a conjugate (C) between (B) or Ab and a diagnostic or therapeutic agent; (13) a kit for detecting (abnormal) expression of TAg; (14) recombinant DNA that includes a promoter region derived from NA; and (15) treatment, diagnosis and monitoring of metastatic cancer associated with (abnormal) expression of TPTE. ACTIVITY : Cytostatic. No biological data given. MECHANISM OF ACTION : Vaccine; Antisense/antibody inhibition of gene expression or activity. |
